Abstract Objective-To determine whether adding L-alanine to the glucose based oral rehydration solution recommended by the World Health Organisation would improve its efficacy in treating acute diarrhoea.
Design-Randomised double blind controlled trial of oral rehydration solution containing L-alanine and glucose.
Setting-Inpatient service of a hospital treating diarrhoea.
Patients-97 Male patients aged 6-59 years admitted to the hospital with acute and severe dehydration due to diarrhoea associated with Vibrio cholerae or enterotoxigenic Escherichia coli. Forty nine received the standard glucose based oral rehydration solution (control group) and 48 this solution with alanine added (study group).
Interventions-All of the patients received rapid intravenous acetate solution for the initial four hours after admission, which fully corrected the signs of dehydration. They were then admitted to the study and randomised. Immediately after the intravenous treatment oral rehydration treatment was started. All of the patients received oral tetracycline for 48 hours, starting 24 hours after start of the study. If signs of dehydration reappeared during oral treatment patients were given rapid intravenous acetate solution until they were fully corrected and then continued to take the assigned oral rehydration solution.
End point-Passage of the last watery stool. Measurements and main results-The median stool output/kg body weight during the initial 24 hours of oral rehydration treatment and until diarrhoea stopped was reduced in the study group compared with the control group from 309 ml to 196 ml and from 393 ml to 236 ml respectively. Intake of oral rehydration solution and intravenous acetate solution was reduced from 455 ml to 308 ml and from 616 ml to 425 ml respectively. Two patients in the study group compared with 18 patients in the control group required unscheduled rapid intravenous acetate solution to correct signs of dehydration during oral rehydration treatment.
Conclusion-Oral rehydration solution contatlning L-alanine was considerably better than standard oral rehydration solution at reducing the severity of symptoms and the need for fluid of male patients with diarrhoea associated with V cholerae and entefotoxigenic E coli.
Introduction
Treatment with glucose based oral rehydration solution is effective for preventing and treating diarrhoea.'-' It does not, however, reduce the volume or frequency of stools or the duration of diarrhoea. The sample size (49 patients in each treatment group) was calculated as being sufficient to detect a 25% decrease in stool output with a type I error of 0 05 and type II error of 0 10. Packets of the control and study oral rehydration solutions were provided by the diarrhoeal diseases control programme. They were identical in appearance and numbered sequentially according to a randomisation chart that was retained by the programme in Geneva. At the end of the study we were given the chart, which identified the two treatment groups. The full identity of the groups was provided only after the analysis was completed.
The study formulation contained glucose 90 mmol/l and alanine 90 mmol/l, whereas the WHO formula, which was given to control patients, contained glucose 111 mmol/l. The total osmolality of the study solution was 400 mmol/kg, which was higher than that of the WHO solution (331 mmol/kg) but was considered to be within the limits of physiological tolerance. The salt content of the control and study formulations was identical-that is, sodium chloride 60 mmol/l, potassium chloride 20 mmol/l, and trisodium citrate dihydrate 10 mmol/l. Immediately after admission the weight and clinical signs of the patients were recorded and rapid intravenous rehydration with acetate solution was started. The amount of fluid given was calculated to replace the estimated deficit and the continuing stool losses; the intravenous solution contained sodium 134 mmol/l, chloride 99 mmol/l, potassium 13 mmol/l, and the equivalent of bicarbonate (in the form of acetate) 48 mmol/l. All patients received intravenous treatment for about four hours, which corrected the signs of dehydration completely. They were then admitted to the study and randomised. The patients were put on cholera cots for separate collection of stools and urine. Immediately after intravenous solution had been given oral rehydration treatment was started. Forty nine patients received the standard WHO oral rehydration solution (control group) and 48 patients the oral rehydration solution containing alanine (study group). The patients drank the solutions from cups as needed. The containers with the assigned solution and the cups were kept at the patients' bedsides. Intake of fluid and output of stools and urine were measured and vital signs summarised every eight hours until the patient was discharged from the study. The nurses were experienced in collection of metabolic samples. The patients fasted during the initial 24 hours of oral rehydration treatment, after which they were offered the standard hospital diet of rice, lentils, fish, and vegetables. Water was offered with the food. All patients received oral tetracycline for 48 hours (500 mg every six hours for adults and 50 mg/kg/day divided into four doses for children) starting 24 hours after the start of oral rehydration.
If signs of dehydration reappeared during oral rehydration with a rise in packed cell volume and specific gravity of plasma patients were again given rapid intravenous acetate solution until signs of dehydration were fully corrected and then given their assigned oral rehydration solution. Data from these patients were included in the analysis. Diarrhoea was considered to have stopped when the last liquid stool was passed. Patients were discharged from the study after passing the first formed stool.
On admission specimens of stools obtained with catheters or material from rectal swabs were cultured for Vibrio cholerae and enterotoxigenic Escherichia coli.
Colonies of E coli were tested for heat labile and heat stable enterotoxins by enzyme linked immunosorbent assay (ELISA).16 Venous blood was collected on admission (0 hours), when oral rehydration treatment was started (at about four hours), 24 hours after oral treatment was started, and at discharge. It was analysed for packed cell volume and specific gravity of NIasma (Total Solid meter, American Optical Company). Serum sodium, potassium, and chloride and total carbon dioxide concentrations were measured with ion selective electrodes (Ion Selective Electrode-E4 analyser, Beckman).
The two groups of patients were compared with regard to median (quartile) values and ranges of several variables on admission: age, weight, duration of diarrhoea before admission, number of stools, vomiting, proportion with history of vomiting, amount of intravenous fluid needed for initial rehydration, and pathogens isolated.
The distribution of important outcome variablesfor example, stool output (ml/kg), intake of oral rehydration solution (ml/kg), duration of diarrhoea (hours), total intake of salt solutions (that is, oral rehydration solutions and intravenous fluids (ml/kg)-was evaluated. Most distributions were positively skewed, but loge transformation rendered them negatively skewed. The outcome variables are therefore summarised as median (quartile) values and ranges. The Wilcoxon rank sum test for groups of independent samples was used to test outcome variables. The X2 test was used for dichotomous variables-for example, the number of patients requiring unscheduled intravenous treatment.
Results
One patient in the study group was excluded from the analysis because a stool collected at the beginning of the study was accidentally lost. Three other patients in the study group were excluded because they had little purging after oral rehydration was started. Data on the two groups before intervention were comparable (table I) . Enteropathogens, predominantly V cholerae, were isolated from 84% of the patients. Thirty two patients in the control group and 26 in the study group were positive for V cholerae. Separate analysis of patients whose cultures grew V cholerae gave results that were nearly identical with those obtained from all patients. Therefore results of combined analysis irrespective of the cause of the diarrhoea is given. Table II shows that in the study group compared with the control group the median stool output/kg body weight during the initial 24 hours of oral rehydration treatment and until diarrhoea stopped was reduced by 37% (309 ml to 196 ril; p= 0-0001) and 40% (393 ml to 236 ml; p=00003) respectively; intake of oral rehydration solution/kg during the initial 24 hours and until diarrhoea stopped was reduced by 23% (391 ml to 300 ml; p=0 036) and 27% (574 ml to 416 ml; p=0004) respectively; total intake of salt solutions/kg-that is, oral rehydration solution and intravenous fluid-during the initial 24 hours of oral rehydration treatment and until diarrhoea stopped was reduced by 32% (455 ml to 308 ml; p=0-001) and 31% (616 ml to 425 ml; p=0O0006) respectively; and duration of diarrhoea was reduced by 15% (52 hours to 44 hours; p=0-10). Similar results were noted when only patients with cultures that grew V cholerae were included in the analysis: the mean (SD) total stool output in the control and study groups was 578 (272) and 337 (126) ml/kg (p=00001) respectively (a reduction of 42%). Eighteen patients in the control group needed additional intravenous solution after starting oral rehydration treatment compared with only two patients in the study group (p<00004).
Values for specific gravity of plasma and packed cell volume on admission and during treatment were closely similar in the two groups (table III) , which was to be expected, 20 patients showing signs of dehydration after starting oral rehydration treatment were rehydrated promptly with intravenous solution. Serum electrolyte and total carbon dioxide concentrations were also similar in the two groups. None of the patients in either group had hypernatraemia on admission, nor did any of the patients develop it during treatment.
Discussion
Our results show that an oral rehydration solution containing alanine and glucose enhanced absorption in adults and older children with severe diarrhoea associated with V cholerae and enterotoxigenic E coli.
In addition it considerably reduced the need for additional intravenous fluids after initial rehydration. The results suggest that the test solution was absorbed more efficiently than the standard solution, even though it had a higher osmolality, which may have imposed an "osmotic penalty." This penalty may be overcome by reducing the glucose or L-alanine concentration or by replacing glucose with glucose polymers.
The estimated efficacy of the solution may be considered to be conservative, because three patients from the study group with little purging after oral rehydration was started were excluded from the analysis; also, after starting oral rehydration treatment 18 patients in the control group compared with two in the study group received additional intravenous solution which may have reduced their faecal output. An The table shows the results. In men aged -75 low diastolic blood pressure was associated with the greatest all cause (p=0 04) and cardiovascular (p=0 02) mortality and higher diastolic blood pressure predicted survival. By contrast, in younger men and in women of all age groups the usual positive association between blood pressure and death due to all causes or cardiovascular disease was found.
Comment
Our analysis confirms a paradoxical graded survival advantage in men aged 3r75 with increasing diastolic blood pressure for both all cause and cardiovascular mortality. This relation was not seen in women or younger men. The relation between systolic blood pressure and survival was not conclusive.
The previous study of this relation from Finland looked at mainly women (82%) and results were for both sexes combined.' In the present study, which included similar numbers of men and women, we were unable to find a positive relation between blood pressure and survival in women. Our population was younger than the Finnish cohort: in the ¢r75 age group the mean age was 78-1 years (78-0 for men and 78-3 for women), whereas the mean age in the Finnish cohort was 88-4 years. The strong inverse relation seen in the oldest men between diastolic blood pressure and cardiovascular death and the high proportion of deaths
